Design of new drugs for medullary thyroid carcinoma

Yanqing Li; Ziyu Luo; Xinxing Wang; Songtao Zhang; Hu Hei; Jianwu Qin

doi:10.3389/fonc.2022.993725

Design of new drugs for medullary thyroid carcinoma

Front Oncol. 2022 Dec 5:12:993725. doi: 10.3389/fonc.2022.993725. eCollection 2022.

Authors

Yanqing Li^{1

2}, Ziyu Luo^{1

2}, Xinxing Wang³, Songtao Zhang^{1

2}, Hu Hei^{1

2}, Jianwu Qin^{1

2}

Affiliations

¹ Department of Thyroid and Neck, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
² The Medical School of Zhengzhou University, Zhengzhou, China.
³ Department of Pain and Rehabilitation and Palliative Medicine, Henan Cancer Hospital, Zhengzhou, China.

Abstract

Medullary thyroid carcinoma (MTC) is one of the common malignant endocrine tumors, which seriously affects human health. Although surgical resection offers a potentially curative therapeutic option to some MTC patients, most patients do not benefit from it due to the difficulty to access the tumors and tumor metastasis. The survival rate of MTC patients has improved with the recent advances in the research, which has improved our understanding of the molecular mechanism underlying MTC and enabled the development and approval of novel targeted drugs. In this article, we reviewed the molecular mechanisms related to MTC progression and the principle for the design of molecular targeted drugs, and proposed some future directions for prospective studies exploring targeted drugs for MTC.

Keywords: designed principle; medullary thyroid carcinoma; molecular mechanism; progression; targeted drug.

Publication types

Systematic Review